TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26762910

Group type: EXPERIMENTAL
Intervention: Amphilimus-eluting stents (AES)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Everolimus-eluting stents (EES)
Number of subjects: 112
Study: 24760401

Group type: EXPERIMENTAL
Intervention: Icosapent ethyl (IPE) 4 g/day co-administered with warfarin 25 mg
Number of subjects: 25

Group type: COMPARATOR
Intervention: Warfarin 25 mg without IPE
Number of subjects: 25
Study: 22087805

Group type: EXPERIMENTAL
Intervention: Toothpaste containing aloe vera
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo toothpaste
Number of subjects: 90

Group type: COMPARATOR
Intervention: Toothpaste with polymer and fluoride containing triclosan
Number of subjects: 90
Study: 20334770

Group type: EXPERIMENTAL
Intervention: n-of-1 trials
Number of subjects: 0
Study: 18942671

Group type: EXPERIMENTAL
Intervention: Increased co-payments for PBS medicines (24% increase in January 2005)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Increased co-payments for PBS medicines
Number of subjects: 17
Study: 15966872

Group type: EXPERIMENTAL
Intervention: Ultrasonic scaler (US group)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Gracey curettes (CC group)
Number of subjects: 12
Study: 11878061

Group type: EXPERIMENTAL
Intervention: Combination of enalapril and losartan
Number of subjects: 186

Group type: COMPARATOR
Intervention: Enalapril alone
Number of subjects: 186

Group type: COMPARATOR
Intervention: Losartan alone
Number of subjects: 186

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 186
Study: 11055597

Group type: EXPERIMENTAL
Intervention: Ceftibuten (once daily for 5 days)
Number of subjects: 248

Group type: COMPARATOR
Intervention: Azithromycin (for 3 days)
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Ceftibuten
Number of subjects: 248

Group type: COMPARATOR
Intervention: Azithromycin
Number of subjects: 248
Study: 9346386

Group type: EXPERIMENTAL
Intervention: HCV genotype 1b
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: HCV genotype 2a
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: HCV genotyping by RT‐PCR
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Type-specific antibodies detection
Number of subjects: 101
Study: 8455312

Group type: EXPERIMENTAL
Intervention: Casein-based enteral nutrition product (1000 kcal, 34 g of proteins)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo capsule
Number of subjects: 51
Study: 3954936

Group type: EXPERIMENTAL
Intervention: Brotizolam with ethanol (0.25 mg dose)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Brotizolam with placebo
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Brotizolam with ethanol
Number of subjects: 13
Study: 28922787

Group type: EXPERIMENTAL
Intervention: Letrozole for 2.5 years
Number of subjects: 1824

Group type: COMPARATOR
Intervention: Letrozole for 5 years
Number of subjects: 1824
Study: 27378679

Group type: EXPERIMENTAL
Intervention: Sitting posture during rounds
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standing posture during rounds
Number of subjects: 0
Study: 24219394

Group type: EXPERIMENTAL
Intervention: Exposure to misleading information
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Arousal
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Negative valence and arousal
Number of subjects: 0

Group type: COMPARATOR
Intervention: Previous exposure to misinformation
Number of subjects: 0
Study: 22164329

Group type: EXPERIMENTAL
Intervention: Breathing Awareness Meditation (BAM)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Health Education Control (HEC)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Life Skills Training (LST)
Number of subjects: 162
Study: 20692567

Group type: EXPERIMENTAL
Intervention: Aspheric Tecnis intraocular lens (IOL)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Sensar AR40e spherical IOL
Number of subjects: 28
Study: 18793562

Group type: EXPERIMENTAL
Intervention: Exercise training during hemodialysis (Group A)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Sedentary control group (Group B)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Healthy control group (Group C)
Number of subjects: 43
Study: 15733875

Group type: EXPERIMENTAL
Intervention: Oral misoprostol 50 mug orally every 4 h
Number of subjects: 200

Group type: COMPARATOR
Intervention: Intracervical dinoprostone 0.5 mg every 6 h
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Maternal and neonatal outcomes
Number of subjects: 200
Study: 12938066

Group type: EXPERIMENTAL
Intervention: 25 mg of amitriptyline
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 30 mg of mirtazapine
Number of subjects: 60
Study: 11069330

Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 0

Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All groups (Isoflurane, Sevoflurane, Desflurane)
Number of subjects: 0
Study: 8676277

Group type: EXPERIMENTAL
Intervention: Bioresorbable matrix barrier (test)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Non-resorbable expanded polytetrafluoroethylene membrane (control)
Number of subjects: 12
Study: 31570179

Group type: EXPERIMENTAL
Intervention: 200 mg L-DOPA
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: 100 mg L-DOPA
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 30562352

Group type: EXPERIMENTAL
Intervention: High-frequency messaging (HFM)
Number of subjects: 1369

Group type: EXPERIMENTAL
Intervention: Low-frequency messaging (LFM)
Number of subjects: 1369

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1369
Study: 27344610

Group type: EXPERIMENTAL
Intervention: Thin dolls (Barbie™) dressed in a swimsuit
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Thin dolls (Barbie™) dressed in modest clothing
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Full-figured dolls (Tracy™) dressed in a swimsuit
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Full-figured dolls (Tracy™) dressed in modest clothing
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Unfamiliar thin dolls dressed in a swimsuit
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Unfamiliar thin dolls dressed in modest clothing
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Unfamiliar full-figured dolls dressed in a swimsuit
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Unfamiliar full-figured dolls dressed in modest clothing
Number of subjects: 112
Study: 24630611

Group type: EXPERIMENTAL
Intervention: Children with NF1
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (typical development)
Number of subjects: 0
Study: 22677735

Group type: EXPERIMENTAL
Intervention: Video eyewear with nitrous oxide/oxygen sedation (group NE)
Number of subjects: 38

Group type: COMPARATOR
Intervention: No video eyewear with nitrous oxide/oxygen sedation (group N)
Number of subjects: 38
Study: 18450126

Group type: EXPERIMENTAL
Intervention: Echinacea (3 capsules twice daily for 8 weeks)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo (parsley, 3 capsules twice daily for 8 weeks)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Echinacea
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 16621618

Group type: EXPERIMENTAL
Intervention: Intravenous methyl prednisolone for 5 days along with antiepileptic drug
Number of subjects: 52

Group type: COMPARATOR
Intervention: Antiepileptic drug monotherapy
Number of subjects: 52
Study: 14615654

Group type: EXPERIMENTAL
Intervention: Epoetin alfa 40,000 to 60,000 U once weekly (QW)
Number of subjects: 285

Group type: COMPARATOR
Intervention: Epoetin alfa 100 to 300 U/kg three times weekly (TIW)
Number of subjects: 285
Study: 11063978

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 0
Study: 9157582

Group type: EXPERIMENTAL
Intervention: Combined prescription and monitoring charts for heparin
Number of subjects: 700

Group type: EXPERIMENTAL
Intervention: Combined prescription and monitoring charts for warfarin
Number of subjects: 700

Group type: COMPARATOR
Intervention: Control (no charts)
Number of subjects: 700
Study: 1286541

Group type: EXPERIMENTAL
Intervention: Long acting crystalline zinc insulin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Glibenclamide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (baseline measurements)
Number of subjects: 0
Study: 29552775

Group type: EXPERIMENTAL
Intervention: Enhanced Recovery After Surgery (ERAS)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Conventional management procedures (Regular group)
Number of subjects: 114
Study: 27281638

Group type: EXPERIMENTAL
Intervention: Mindfulness-based worksite intervention (eight-week mindfulness training, e-coaching, and supporting elements)
Number of subjects: 257

Group type: COMPARATOR
Intervention: Usual practice (control group)
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: Mindfulness-based worksite intervention
Number of subjects: 257
Study: 23940000

Group type: EXPERIMENTAL
Intervention: Topical atorvastatin 1% ointment applied once/day for 14 days
Number of subjects: 104
Study: 22341565

Group type: EXPERIMENTAL
Intervention: Strength training
Number of subjects: 72

Group type: COMPARATOR
Intervention: Aerobic exercise
Number of subjects: 72
Study: 20038732

Group type: EXPERIMENTAL
Intervention: Mitoxantrone/cytarabine/etoposide
Number of subjects: 1658

Group type: COMPARATOR
Intervention: Cytarabine/daunorubicin/etoposide
Number of subjects: 1658

Group type: EXPERIMENTAL
Intervention: Daunorubicin/cytarabine/thioguanine (S-DAT)
Number of subjects: 1658

Group type: EXPERIMENTAL
Intervention: Daunorubicin/cytarabine/thioguanine (H-DAT)
Number of subjects: 1658

Group type: EXPERIMENTAL
Intervention: Four courses of chemotherapy
Number of subjects: 1658

Group type: EXPERIMENTAL
Intervention: Transplantation as final course
Number of subjects: 1658

Group type: EXPERIMENTAL
Intervention: Five courses of chemotherapy
Number of subjects: 1658
Study: 18537469

Group type: EXPERIMENTAL
Intervention: Japanese acupuncture (JA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham acupuncture using the Streitberger device and sham moxibustion
Number of subjects: 0
Study: 16609319

Group type: EXPERIMENTAL
Intervention: Network-based geriatric rehabilitation programme
Number of subjects: 741

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 741
Study: 14638354

Group type: EXPERIMENTAL
Intervention: Epoetin alfa (40,000 units, s.c. once weekly)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Standard of care (SOC) for anemia management (RBV dose reduction or discontinuation, transfusions)
Number of subjects: 64
Study: 10972451

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment (CBT) for panic disorder, 12 hours in addition to regular alcoholism treatment program.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Regular alcoholism treatment program (Control group).
Number of subjects: 0
Study: 8855742

Group type: EXPERIMENTAL
Intervention: Endoscopic variceal ligation (EVL)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Endoscopic injection sclerotherapy (EIS)
Number of subjects: 44
Study: 1738796

Group type: EXPERIMENTAL
Intervention: Physostigmine (0.75 mg SC)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Hyoscine (1.2 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Temazepam (20 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Flecainide (200 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 6380695

Group type: EXPERIMENTAL
Intervention: Levamisole
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study: 29402358

Group type: EXPERIMENTAL
Intervention: Early mobilization (joint activity, standing to the bed, 3 times a day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (standard treatment without early mobilization)
Number of subjects: 60
Study: 27332197

Group type: EXPERIMENTAL
Intervention: Personal Health Network (PHN)
Number of subjects: 12
Study: 24701731

Group type: EXPERIMENTAL
Intervention: Fresh gas flow (FGF) rate at 0.5 L x min(‐1)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Fresh gas flow (FGF) rate at 1 L x min(‐1)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Fresh gas flow (FGF) rate at 2 L x min(‐1)
Number of subjects: 30
Study: 22108830

Group type: EXPERIMENTAL
Intervention: Immediate invasive approach (<2 h after randomization)
Number of subjects: 602

Group type: COMPARATOR
Intervention: Early invasive approach (10-48 h after randomization)
Number of subjects: 602

Group type: COMPARATOR
Intervention: Selective invasive approach (high invasive percentage, >48 h after randomization)
Number of subjects: 602

Group type: EXPERIMENTAL
Intervention: Immediate invasive approach
Number of subjects: 602

Group type: COMPARATOR
Intervention: Early invasive approach
Number of subjects: 602

Group type: COMPARATOR
Intervention: Selective invasive approach
Number of subjects: 602
Study: 20829701

Group type: EXPERIMENTAL
Intervention: TruView EVO2 laryngoscope (Group T, n = 25)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Miller laryngoscope (Group M, n = 25)
Number of subjects: 50
Study: 18325863

Group type: EXPERIMENTAL
Intervention: Immunonutrition (enteral nutrition supplemented with glutamine, arginine, and/or omega-3 fatty acids)
Number of subjects: 3
Study: 16878408

Group type: EXPERIMENTAL
Intervention: Surgical resection
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chemo-radiation therapy
Number of subjects: 0
Study: 12749498

Group type: EXPERIMENTAL
Intervention: Permethrin-treated bed nets (ITNs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intervention homes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Willingness to pay for bed nets
Number of subjects: 0
Study: 8822163

Group type: EXPERIMENTAL
Intervention: Relational processing tasks (category sorting)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Relational processing tasks (narrative construction)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Relational processing tasks (relational imagery)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Item-specific processing tasks (pleasantness ratings)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Item-specific processing tasks (familiarity ratings)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Item-specific processing tasks (single imagery)
Number of subjects: 0
Study: 1359978

Group type: EXPERIMENTAL
Intervention: metipranolol 0.3%
Number of subjects: 7

Group type: COMPARATOR
Intervention: timolol maleate 0.5%
Number of subjects: 7
Study: 3926729

Group type: EXPERIMENTAL
Intervention: Insulin infusion added to parenteral feed
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Insulin infusion
Number of subjects: 6

Group type: COMPARATOR
Intervention: Without insulin
Number of subjects: 6
Study: 31395104

Group type: EXPERIMENTAL
Intervention: Bilateral decompression via unilateral laminotomy (BDUL)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional laminectomy (CL)
Number of subjects: 50
Study: 30640244

Group type: EXPERIMENTAL
Intervention: Local infiltration analgesia (LIA) with bupivacaine and levobupivacaine 2 mg/kg and adrenaline 0.5 mg
Number of subjects: 43

Group type: COMPARATOR
Intervention: Intrathecal morphine 0.3 mg
Number of subjects: 43
Study: 27992826

Group type: EXPERIMENTAL
Intervention: Brief cognitive intervention
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 47
Study: 26011733

Group type: EXPERIMENTAL
Intervention: Single dose praziquantel (40 mg/kg body weight)
Number of subjects: 1017

Group type: EXPERIMENTAL
Intervention: Double dose praziquantel (40 mg/kg body weight, second dose 2 weeks later)
Number of subjects: 1017

Group type: EXPERIMENTAL
Intervention: Both treatment regimens
Number of subjects: 1017
Study: 23616162

Group type: EXPERIMENTAL
Intervention: 8OHdG levels measured by LCMS assay
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: 8OHdG levels measured by LCECA assay
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: 8OHdG levels measured by LCMS and LCECA assays
Number of subjects: 160
Study: 21599990

Group type: EXPERIMENTAL
Intervention: Web-based dietary intervention for 6 months in addition to standard diabetes care
Number of subjects: 82

Group type: COMPARATOR
Intervention: Standard diabetes care
Number of subjects: 82
Study: 19029226

Group type: EXPERIMENTAL
Intervention: r-metHuLeptin treatment
Number of subjects: 118

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study: 16738291

Group type: EXPERIMENTAL
Intervention: 18G Special Sprotte needle
Number of subjects: 1077

Group type: COMPARATOR
Intervention: 17G Tuohy needle
Number of subjects: 1077
Study: 15326246

Group type: EXPERIMENTAL
Intervention: Strength training of elbow flexors and ankle dorsiflexors
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Albuterol (sustained-release, 8 mg BID)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Non-training (placebo)
Number of subjects: 65
Study: 11765072

Group type: EXPERIMENTAL
Intervention: BeamCath technique (76 Gy)
Number of subjects: 267

Group type: COMPARATOR
Intervention: Conventional techniques (placebo)
Number of subjects: 267
Study: 9401646

Group type: EXPERIMENTAL
Intervention: Exogenous GLP-1 [7-36 amide] infusion (0.4, 0.8 pmol kg-1 min-1)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Liquid mixed meal (50 g sucrose in 400 ml 8% amino acid)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo (control for GLP-1 infusion)
Number of subjects: 9
Study: 8221563

Group type: EXPERIMENTAL
Intervention: GM-CSF (5.5 micrograms/kg protein dosage per day from day-6 to day-4 before chemotherapy)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Chemotherapy only (without GM-CSF)
Number of subjects: 12
Study: 3304564

Group type: EXPERIMENTAL
Intervention: Methohexital (0.1 mg/kg/min continuous infusion)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Thiopental (5 mg/kg I.V. bolus)
Number of subjects: 60
Study: 29055710

Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC)
Number of subjects: 436

Group type: COMPARATOR
Intervention: Control (sham intervention)
Number of subjects: 436
Study: 27927175

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (CBT) intervention
Number of subjects: 30

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 30
Study: 24901077

Group type: EXPERIMENTAL
Intervention: Narrow elastic cuffs
Number of subjects: 16

Group type: COMPARATOR
Intervention: Narrow nylon cuffs
Number of subjects: 16
Study: 23122924

Group type: EXPERIMENTAL
Intervention: Plastibell (PD)
Number of subjects: 198

Group type: COMPARATOR
Intervention: Conventional dissection (CDS)
Number of subjects: 198
Study: 20118151

Group type: EXPERIMENTAL
Intervention: Vascular closure device (VCD)
Number of subjects: 11621

Group type: COMPARATOR
Intervention: No vascular closure device (No VCD)
Number of subjects: 11621

Group type: EXPERIMENTAL
Intervention: Bivalirudin monotherapy with VCD
Number of subjects: 11621

Group type: EXPERIMENTAL
Intervention: Bivalirudin monotherapy
Number of subjects: 11621

Group type: EXPERIMENTAL
Intervention: VCD
Number of subjects: 11621
Study: 18298700

Group type: EXPERIMENTAL
Intervention: Topiramate 50 mg/day
Number of subjects: 1580

Group type: EXPERIMENTAL
Intervention: Topiramate 100 mg/day
Number of subjects: 1580

Group type: EXPERIMENTAL
Intervention: Topiramate 200 mg/day
Number of subjects: 1580

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1580

Group type: EXPERIMENTAL
Intervention: Topiramate (all doses combined)
Number of subjects: 1580
Study: 16850316

Group type: EXPERIMENTAL
Intervention: Slow walk (4.0 km h(‐1))
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: Fast walk (5.6 km h(‐1))
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: Run (8.0 km h(‐1))
Number of subjects: 295

Group type: COMPARATOR
Intervention: Rest
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: All conditions
Number of subjects: 295
Study: 14634678

Group type: EXPERIMENTAL
Intervention: Orlistat (120 mg)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 10824049

Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Lisinopril 10 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Combination of 2.5 mg amlodipine and 5 mg lisinopril
Number of subjects: 24

Group type: COMPARATOR
Intervention: Amlodipine (2.5 mg and 5 mg) and Lisinopril (5 mg and 10 mg)
Number of subjects: 24
Study: 8863761

Group type: EXPERIMENTAL
Intervention: Supervised (physical therapist‐instructed) group (n = 47)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Brochure group (n = 40)
Number of subjects: 87
Study: 1378112

Group type: EXPERIMENTAL
Intervention: Nifedipine SR (50-100 mg once daily)
Number of subjects: 269

Group type: COMPARATOR
Intervention: Conventional nifedipine tablet (20-40 mg twice daily)
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Nifedipine SR
Number of subjects: 269

Group type: COMPARATOR
Intervention: Conventional nifedipine tablet
Number of subjects: 269
Study: 7041665

Group type: EXPERIMENTAL
Intervention: Albendazole 400 mg single dose in adults
Number of subjects: 392

Group type: EXPERIMENTAL
Intervention: Albendazole 400 mg per day for 3 consecutive days
Number of subjects: 392

Group type: EXPERIMENTAL
Intervention: Albendazole 200 mg in children
Number of subjects: 392

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 392
Study: 31788029

Group type: EXPERIMENTAL
Intervention: Autologous skin cell suspension (ReCell®)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Standard care interventions
Number of subjects: 150
Study: 29912135

Group type: EXPERIMENTAL
Intervention: HALC
Number of subjects: 46

Group type: COMPARATOR
Intervention: LAC
Number of subjects: 46
Study: 26899484

Group type: EXPERIMENTAL
Intervention: Local infiltration analgesia (LIA) with ropivacaine and epinephrine
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (no infiltration)
Number of subjects: 150
Study: 25132247

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (loading dose of 1 μg/kg followed by 0.2 μg/kg per h infusion)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 80

Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 80
Study: 18263874

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 115
Study: 15871360

Group type: EXPERIMENTAL
Intervention: Topical administration of brimonidine tartrate
Number of subjects: 0